Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?
Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene.
The U.S. Preventive Services Task Force recommends that women who are at increased risk of primary breast cancer consider taking preventive medications such as tamoxifen.
Sign Up for Free e-newsletters
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- Myelofibrosis: From Diagnosis to Early Intervention
- FDA Approves HPV Vaccine for People Through Age 45
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Strength and Hope for Women in the Mist of Cancer
- Prospective Study Measures Cognitive, Treatment Effects in Older Breast Cancer Survivors
- Immune Checkpoint Inhibitor Therapy May Affect Thyroid Function
- Hypofractionated Radiotherapy After Conservative Surgery May Increase Low-intermediate Grade Late Fibrosis in Breast Cancer Patients
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|